Investor Relations : BioMarin

Latest Events

13th Annual Jefferies Global Healthcare Conference 2022
Listen to the Replay

Credit Suisse 31st Annual Healthcare Conference 2022
Listen to the Replay

Press Releases

Nov 23, 2022

BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing...

All Press Releases

Quarterly Results

Doc

BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN^®)

Call

Listen to the 3Q22 CC

All Financial Information

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More

Investor Relations
415-455-7558
IR@BMRN.com

Media & Press
415-455-7451
corporatecommunications2@BMRN.com

Email Alerts